RAPP vs ROL · $532.9M cap vs P/E 41, rev $3.39B
Rapport Therapeutics, Inc. Common Stock (RAPP) versus Rollins Inc (ROL) — a side-by-side from cached financials, not a winner call.
Rapport Therapeutics, Inc. Common Stock (RAPP) is a biotechnology company listed on US.
Rollins Inc (ROL) is a personal services company listed on NYSE.
RAPP does not have a complete income-statement cache yet.
Latest reported ROL revenue for 2024-12-31 was $3.39B. Net income was $466.4M. Revenue was up 10.3% from 2023-12-31 to 2024-12-31. ROL currently screens at market cap $21.73B and trailing P/E 41.4.
RAPP currently screens at market cap $532.9M. ROL currently screens at market cap $21.73B and trailing P/E 41.4.
Not investment advice. Open the RAPP and ROL stock pages for the full models.
Not investment advice.